Elsevier

Leukemia Research

Volume 38, Issue 4, April 2014, Pages 475-483
Leukemia Research

Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival☆☆

https://doi.org/10.1016/j.leukres.2014.01.006Get rights and content
Under a Creative Commons license
open access

Abstract

Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p = 0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p = 0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.

Keywords

Matched-pair analysis
CMML
Chronic myelomonocytic leukemia
Azacitidine
Austrian Azacitidine Registry

Cited by (0)

☆☆

ClinicalTrials.gov identifier: NCT01595295.